Article
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2015
Kris M G, Camidge D R, Giaccone G, Hida T, Li B T, O'Connell J, Taylor I, Zhang H, Arcila M E, Goldberg Z, Jänne P A
Abstract excerpt
BACKGROUND: HER2 mutations and amplifications have been identified as oncogenic drivers in lung cancers. Dacomitinib, an irreversible inhibitor of HER2, EGFR (HER1), and HER4 tyrosine kinases, has demonstrated activity in cell-line models with HER2 exon 20 insertions or amplifications. Here, we studied dacomitinib in patients with HER2-mutant or amplified lung cancers. PATIENTS AND METHODS: As a prespecified...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.